More Competition In Prostate Cancer? Medivation’s Enzalutamide Now With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Medivation and Astellas have submitted their castration-resistant prostate cancer drug enzalutamide to FDA and hope to gain priority review for the long-anticipated therapy.